Regulus Therapeutics EBITDA 2011-2026 | RGLS

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Regulus Therapeutics

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-30.9 M	-28.1 M	-27.4 M	-13.7 M	-15.9 M	-44.5 M	-67.6 M	-79.2 M	-53.2 M	-43.4 M	-16.4 M	-11.6 M	-6.23 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-6.23 M	-79.2 M	-33.7 M

Quarterly EBITDA Regulus Therapeutics

2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-10.5 M	-	-	-	-8.74 M	-	-	-	-7.32 M	-	-7.56 M	-7.12 M	-6.54 M	-	-8.42 M	-6.26 M	-5.46 M	-	-733 K	-6.25 M	-5.41 M	-	-4.19 M	-4 M	-2.24 M	-	-8.18 M	-12.2 M	-15 M	-	-13.5 M	-20 M	-19 M	-	-17.6 M	-20.3 M	-21 M	-	-12.2 M	-20.4 M	-12.5 M	-	-10.6 M	-12.3 M	-10.4 M	-	-1.91 M	-4.06 M	-5.26 M	-	-2.79 M	-2.08 M	-1.96 M	-	-317 K	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-317 K	-21 M	-9.03 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
Acorda Therapeutics ACOR	-233 M	-	-24.86 %	$ 820 K	USA
Adverum Biotechnologies ADVM	-136 M	-	-	$ 86.2 M	USA
AlloVir ALVR	-46.1 M	-	4.14 %	$ 49.1 M	USA
Amgen AMGN	14.2 B	$ 340.0	-0.75 %	$ 183 B	USA
Amneal Pharmaceuticals AMRX	451 M	$ 12.32	-0.24 %	$ 3.86 B	USA
Applied Molecular Transport AMTI	-124 M	-	-	$ 10.1 M	USA
Applied Therapeutics APLT	-64.5 M	-	-	$ 8.42 M	USA
I-Mab IMAB	13.8 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	3.11 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	31.8 M	-	2.54 %	$ 160 B	France
Arcutis Biotherapeutics ARQT	-11.5 M	$ 23.27	-1.63 %	$ 2.96 B	USA
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Autolus Therapeutics plc AUTL	-262 M	$ 1.36	-2.16 %	$ 362 M	Britain
AVROBIO AVRO	10.8 M	-	1083.1 %	$ 745 M	USA
Ayala Pharmaceuticals AYLA	-37.3 M	-	-	$ 7.46 M	Israel
AstraZeneca PLC AZN	1.06 B	-	-	$ 96.9 B	Britain
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	-8.18 M	-	-1.52 %	$ 24.7 M	USA
BeiGene, Ltd. BGNE	589 M	-	0.49 %	$ 251 B	Cayman-islands
Alterity Therapeutics Limited ATHE	-17.3 M	$ 3.76	4.35 %	$ 9.05 B	Australia
CymaBay Therapeutics CBAY	-101 M	-	-	$ 3.45 B	USA
Advaxis ADXS	-35.9 M	-	-9.65 %	$ 45.9 M	USA
Aytu BioScience AYTU	-2.45 M	$ 2.57	-3.38 %	$ 16.1 M	USA
Avid Bioservices CDMO	-7.57 M	-	-	$ 789 M	USA
Cidara Therapeutics CDTX	-176 M	-	-	$ 1.41 B	USA
Институт стволовых клеток человека ISKJ	220 M	-	-	-	Russia
Checkpoint Therapeutics CKPT	-56.2 M	-	-	$ 169 M	USA
Cellectar Biosciences CLRB	-22.8 M	$ 2.75	1.48 %	$ 7.17 M	USA
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
Checkmate Pharmaceuticals CMPI	-61.4 M	-	-	$ 231 M	USA
AgeX Therapeutics AGE	-23.9 M	-	-10.17 %	$ 12.2 K	USA
Concert Pharmaceuticals CNCE	-76 M	-	-	$ 401 M	USA
Aeglea BioTherapeutics AGLE	-242 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	-16.2 M	-	-	$ 26.5 M	USA
CTI BioPharma Corp. CTIC	-77.8 M	-	-	$ 1.2 B	USA
AIkido Pharma AIKI	-55.6 M	-	1.93 %	$ 17.4 M	USA
Aptose Biosciences APTO	22 K	-	-45.71 %	$ 1.2 M	Canada
Cyclacel Pharmaceuticals CYCCP	-8.42 M	-	-4.36 %	$ 27 M	USA
Cyclerion Therapeutics CYCN	-3.63 M	$ 3.48	-16.14 %	$ 8.76 M	USA
Deciphera Pharmaceuticals DCPH	-209 M	-	-	$ 2.18 B	USA
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA
Dynavax Technologies Corporation DVAX	505 K	-	-	$ 2.02 B	USA
CureVac N.V. CVAC	-412 M	-	-	$ 867 M	Germany
Dyadic International DYAI	-7.19 M	$ 0.88	1.66 %	$ 31.8 M	USA
BioNTech SE BNTX	15.3 B	$ 89.62	-1.82 %	$ 27.2 B	Germany
Coherus BioSciences CHRS	-180 M	$ 1.67	-	$ 196 M	USA
Akari Therapeutics, Plc AKTX	-21.6 M	$ 3.8	7.34 %	$ 256 B	Britain
Akouos AKUS	-84.3 M	-	0.23 %	$ 488 M	USA
Allakos ALLK	-190 M	-	-	$ 28.6 M	USA